186
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Health Care Situation in the Treatment of Uncontrolled GINA Step 4/5 Patients in Germany

, ORCID Icon, , , , , , , & ORCID Icon show all
Pages 813-820 | Received 25 May 2023, Accepted 24 Jul 2023, Published online: 04 Aug 2023

References

  • Papaioannou AI, Kostikas K, Zervas E, et al. Control of asthma in real life: still a valuable goal? Eur Respir Rev. 2015;24(136):361–369. doi:10.1183/16000617.00001615
  • Reddel HK, Boulet LP. Global Initiative for Asthma. Global strategy for asthma management and prevention; 2021. Available from: wwwginasthmaorg. Accessed July 26, 2023.
  • Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43:343–373. doi:10.1183/09031936.00202013
  • Bergmann K-C, Skowasch D, Timmermann H, et al. Prevalence of patients with uncontrolled asthma despite NVL/GINA Step 4/5 treatment in Germany. J Asthma Allergy. 2022;15:897–906. doi:10.2147/JAA.S365967
  • Bergmann K-C, Skowasch D, Timmermann H, et al. Prevalence of patients with uncontrolled asthma despite high intensity treatment (NVL/GINA step 4/5) in Germany DGP congress. Pneumologie. 2022;76:S8–9.
  • Rathmann W, Bongaerts B, Carius H, et al. Basic characteristics and representativeness of the German disease analyzer database. Int J Clin Pharmacol Ther. 2018;56:459–466. doi:10.5414/CP203320
  • Bundestag WDD. Anzahl der Ärzte verschiedener Fachrichtungen Statistische Angaben zu Deutschland und ausgewählten europäischen Ländern [Number of physicians in various specialties. Statistical data on Germany and selected European countries]. German Bundestag (Deutscher Bundestag); 2019.
  • Taube C, Bramlage P, Hofer A, Anderson D. Prevalence of oral corticosteroid use in the German severe asthma population. ERJ Open Res. 2019;5:4.
  • Lommatzsch M, Wilmer C, Sauerbeck IS. Prevalence of the use of oral corticosteroids in asthma-a 3-year analysis in Germany. Eur Respir J. 2019;2019:54.
  • Hinds D, Martin S, Nelsen L, et al. Measuring burden of oral corticosteroids in us and German patients with severe asthma. Am J Respir Crit Care Med. 2018;2018:197.
  • Worth H, Criée CP, Vogelmeier CF, et al. Prevalence of overuse of short-acting beta-2 agonists (SABA) and associated factors among patients with asthma in Germany. Respir Res. 2021;22(1). doi:10.1186/s12931-021-01701-3
  • Janson C, Menzies-Gow A, Nan C, et al. SABINA: an overview of short-acting β2-agonist use in asthma in European Countries. Adv Ther. 2020;37(3):1124–1135. doi:10.1007/s12325-020-01233-0
  • Bourdin A, Quinton A, Callan L, et al. Targeted literature review: burden of disease associated with severe and uncontrolled asthma in France, Germany, Italy, Spain and the UK. Eur Respir J. 2020;56. doi:10.1183/13993003.02162-2020
  • Korn S, Koch A, Schulz C, et al. The German severe asthma registry and type 2-high and type 2-low asthma phenotypes. Eur Respir J. 2019;54.
  • Kleine-Tebbe J, Mailänder C. Patterns of allergen sensitization in patients with severe asthma in Germany. J Allergy Clin Immunol. 2020;8(2):744–746.e743.
  • Kleine-Tebbe J, Mailaender C. Epidemiological screening of severe asthma-patients with thorough allergy-testing (ESSAy). Allergy. 2018;73:707.
  • Buhl R, Koch A, Schulz C, et al. Type 2-high and type 2-low airway inflammation in severe asthma. Am J Respir Crit Care Med. 2019;199(9):489–495. doi:10.1164/rccm.201708-1668OC
  • Greulich T, Topfer V, Hennig M, et al. COPD in Germany: use of diagnostic measures including blood eosinophil counts in daily practice. Pneumologie. 2021;75(5):344–352. doi:10.1055/a-1266-6602
  • Kaur R, Chupp G. Phenotypes and endotypes of adult asthma: moving toward precision medicine. J Allergy Clin Immunol. 2019;144:1–12. doi:10.1016/j.jaci.2019.05.031